Seminars in Oncology
Volume 33, Issue 5 , Pages 552-562 , October 2006

Surgical Management of Renal Cell Carcinoma

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106–130
  2. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol. 2001;166:1611–1623
  3. Devesa SS, Silverman DT, McLaughlin JK, et al. Comparison of the descriptive epidemiology of urinary tract cancers. Cancer Causes Control. 1990;1:133–141
  4. Figlin RA. Renal cell carcinoma: Management of advanced disease. J Urol. 1999;161:381–386
  5. Robson C, Churchill B, Andreson W. The results of radical nephrectomy for renal cell carcinoma. J Urol. 1969;101:297–302
  6. Robson CJ. Radical nephrectomy for renal cell carcinoma. J Urol. 1963;89:37–42
  7. Skinner DG, Colvin RB, Vermillion CD, et al. Diagnosis and management of renal cell carcinoma (A clinical and pathologic study of 309 cases). Cancer. 1971;28:1165–1177
  8. Patel NP, Lavengood RW. Renal cell carcinoma: Natural history and results of treatment. J Urol. 1978;119:722–726
  9. Rafla S. Renal cell carcinoma (Natural history and results of treatment). Cancer. 1970;25:26–40
  10. Vermooten V. Indications for conservative surgery in certain renal tumors: Study based on the growth pattern of clear cell carcinoma. J Urol. 1950;64:200–208
  11. Gillenwater J, Howards S. In: The kidney, hypertension and vascular disease: Tumor, in The Year Book of Urology. Chicago, IL: Yearbook Medical; 1981;p. 116–133
  12. Pantuck AJ, Zisman A, Rauch MK, et al. Incidental renal tumors. Urology. 2000;56:190–196
  13. Smith S, Bosniak M, Megibow A, et al. Renal cell carcinoma: Earlier discovery and increased detection. Radiology. 1989;170:699–703
  14. Jayson M, Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma. Urology. 1998;51:203–205
  15. Konnak JW, Grossman HB. Renal cell carcinoma as an incidental finding. J Urol. 1985;134:1094–1096
  16. Luciani LG, Cestari R, Tallarigo C. Incidental renal cell carcinoma-age and stage characterization and clinical implications: Study of 1092 patients (1982-1997). Urology. 2000;56:58–62
  17. Tsui KH, Shvarts O, Smith RB, et al. Renal cell carcinoma: Prognostic significance of incidentally detected tumors. J Urol. 2000;163:426–430
  18. Sweeney JP, Thornhill JA, Graiger R, et al. Incidentally detected renal cell carcinoma: Pathological features, survival trends and implications for treatment. Br J Urol. 1996;78:351–353
  19. Lee CT, Katz J, Shi W, et al. Surgical managment of renal tumors 4 cm. or less in a contemporary cohort. J Urol. 2000;163:730–736
  20. Clark PE, Schover LR, Uzzo RG, et al. Quality of life and psychological adaptation after surgical treatment for localized renal cell carcinoma: Impact of the amount of remaining renal tissue. Urology. 2001;57:252–256
  21. Shinohara N, Harabayashi T, Sato S, et al. Impact of nephron-sparing surgery on quality of life in patients with localized renal cell carcinoma. Eur Urol. 2001;39:114–119
  22. Lau WK, Blute ML, Weaver AL, et al. Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. Mayo Clin Proc. 2000;75:1236–1242
  23. McKiernan J, Simmons R, Katz J, et al. Natural history of chronic renal insufficiency after partial and radical nephrectomy. Urology. 2002;59:816–820
  24. Corman JM, Penson DF, Hur K, et al. Comparison of complications after radical and partial nephrectomy: Results from the National Veterans Administration Surgical Quality Improvement Program. BJU Int. 2000;86:782–789
  25. Shekarriz B, Upadhyay J, Shekarriz H, et al. Comparison of costs and complications of radical and partial nephrectomy for treatment of localized renal cell carcinoma. Urology. 2002;59:211–215
  26. Uzzo RG, Wei JT, Hafez K, et al. Comparison of direct hospital costs and length of stay for radical nephrectomy versus nephron-sparing surgery in the management of localized renal cell carcinoma. Urology. 1999;54:994–998
  27. Frank I, Blute ML, Cheville JC, et al. Solid renal tumors: An analysis of pathological features related to tumor size. J Urol. 2003;170:2217–2220
  28. Dechet C, Sebo T, Farrow G, et al. Prospective analysis of intraoperative frozen needle biopsy of solid renal masses in adults. J Urol. 1999;162:1282–1284
  29. Dechet CB, Zincke H, Sebo TJ, et al. Prospective analysis of computerized tomography and needle biopsy with permanent sectioning to determine the nature of solid renal masses in adults. J Urol. 2003;169:71–74
  30. Kobayashi M, Hashimoto S, Tokue A. Nephron-sparing surgery is still controversial for patients with renal cell carcinoma and normal contralateral kidney: Risks predictable by AgNOR counts in satellite lesions. Mol Urol. 2000;4:21–29
  31. Schlichter A, Wunderlich H, Junker K, et al. Where are the limits of elective nephron- sparing surgery in renal cell carcinoma?. Eur Urol. 2000;37:517–520
  32. Kletscher BA, Qian J, Bostwick DG, et al. Prospective analysis of multifocality in renal cell carcinoma: Influence of histological pattern, grade, number, size, volume and deoxyribonucleic acid ploidy. J Urol. 1995;153:904–906
  33. Moll V, Becht E, Ziegler M. Kidney preserving surgery in renal cell tumors: Indications, techniques and results in 152 patients. J Urol. 1993;150:319–323
  34. Lerner SE, Hawkins CA, Blute ML, et al. Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery. J Urol. 1996;155:1868–1873
  35. Licht MR, Novick AC, Goormastic M. Nephron sparing surgery in incidental versus suspected renal cell carcinoma. J Urol. 1994;152:39–42
  36. Butler BP, Novick AC, Miller DP, et al. Management of small unilateral renal cell carcinomas: radical versus nephron-sparing surgery. Urology. 1995;45:34–40
  37. Hafez KS, Fergany AF, Novick AC. Nephron sparing surgery for localized renal cell carcinoma: Impact of tumor size on patient survival, tumor recurrence and TNM staging. J Urol. 1999;162:1930–1933
  38. Zisman A, Pantuck AJ, Chao D, et al. Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4.5 rather than 7 cm. better correlates with clinical outcome. J Urol. 2001;166:54–58
  39. Lau WK, Cheville JC, Blute ML, et al. Prognostic features of pathologic stage T1 renal cell carcinoma after radical nephrectomy. Urology. 2002;59:532–537
  40. Kovacs G, Akhtar M, Beckwith BJ, et al. The Heidelberg classification of renal cell tumours. J Pathol. 1997;183:131–133
  41. Amin MB, Tamboli P, Javidan J, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: An experience of 405 cases. Am J Surg Pathol. 2002;26:281–291
  42. Kattan MW, Reuter V, Motzer RJ, et al. A postoperative prognostic nomogram for renal cell carcinoma. J Urol. 2001;166:63–67
  43. Hafez KS, Novick AC, Butler BP. Management of small solitary unilateral renal cell carcinomas: Impact of central versus peripheral tumor location. J Urol. 1998;159:1156–1160
  44. Cheville JC, Blute ML, Zincke H, et al. Stage pT1 conventional (clear cell) renal cell carcinmoa: Pathological features associated with cancer specific survival. J Urol. 2001;166:453–456
  45. Leibovich BC, Blute ML, Cheville JC, et al. Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol. 2004;171:1066–1070
  46. Novick AC, Zincke H, Neves RJ, et al. Surgical enucleation for renal cell carcinoma. J Urol. 1986;135:235–238
  47. Sutherland SE, Resnick MI, Maclennan GT, et al. Does the size of the surgical margin in partial nephrectomy for renal cell cancer really matter?. J Urol. 2002;167:61–64
  48. Kletscher BA, Qian J, Bostwick DG, et al. Prospective analysis of the incidence of ipsilateral adrenal metastasis in localized renal cell carcinoma. J Urol. 1996;155:1844–1846
  49. Tsui KH, Shvarts O, Barbaric Z, et al. Is adrenalectomy a necessary component of radical nephrectomy? (UCLA experience with 511 radical nephrectomies). J Urol. 2000;163:437–441
  50. Blute ML, Leibovich BC, Cheville JC, et al. A protocol for performing extended lymph node dissection using primary tumor pathological features for patients treated with radical nephrectomy for clear cell renal cell carcinoma. J Urol. 2004;172:465–469
  51. Minervini A, Lilas L, Morelli G, et al. Regional lymph node dissection in the treatment of renal cell carcinoma: Is it useful in patients with no suspected adenopathy before or during surgery?. BJU Int. 2001;88:169–172
  52. Pantuck AJ, Zisman A, Dorey F, et al. Renal cell carcinoma with retroperitoneal lymph nodes (Impact on survival and benefits of immunotherapy). Cancer. 2003;97:2995–3002
  53. Pantuck AJ, Zisman A, Dorey F, et al. Renal cell carcinoma with retroperitoneal lymph nodes: Role of lymph node dissection. J Urol. 2003;169:2076–2083
  54. Terrone C, Guercio S, De Luca S, et al. The number of lymph nodes examined and staging accuracy in renal cell carcinoma. BJU Int. 2003;91:37–40
  55. Blom JH, van Poppel H, Marechal JM, et al. Radical nephrectomy with and without lymph node dissection: Preliminary results of the EORTC randomized phase III protocol 30881 (EORTC Genitourinary Group). Eur Urol. 1999;36:570–575
  56. Wood CG. The role of cytoreductive nephrectomy in the management of metastatic renal cell carcinoma. Urol Clin North Am. 2003;30:581–588
  57. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996;335:865–875
  58. Neves RJ, Zincke H, Taylor WF. Metastatic renal cell cancer and radical nephrectomy: Identification of prognostic factors and patient survival. J Urol. 1988;139:1173–1176
  59. Kirkali Z, Tuzel E, Mungan MU. Recent advances in kidney cancer and metastatic disease. BJU Int. 2001;88:818–824
  60. Fishman M, Seigne J. Immunotherapy of metastatic renal cell cancer. Cancer Control. 2002;9:293–304
  61. Novick AC, Campbell SC. Renal tumours. In:  Walsh PS, et al. editor. Campbell’s Urology. Philadelphia, PA: Saunders; 2002;p. 2672–2772
  62. Flanigan RC. Role of surgery in patients with metastatic renal cell carcinoma. Semin Urol Oncol. 1996;14:227–229
  63. Yonover PM, Sharma SK, Flanigan RC. Role of nephrectomy in metastatic kidney cancer. Cancer Treat Res. 2003;116:119–135
  64. Munro NP, Woodhams S, Nawrocki JD, et al. The role of transarterial embolization in the treatment of renal cell carcinoma. BJU Int. 2003;92:240–244
  65. Volkmer BG, Gschwend JE. Value of metastases surgery in metastatic renal cell carcinoma. Urol A. 2002;41:225–230
  66. Olerud C, Jonsson B. Surgical palliation of symptomatic spinal metastases. Acta Orthop Scand. 1996;67:513–522
  67. Wedin R. Surgical treatment for pathologic fracture. Acta Orthop Scand Suppl. 2001;72:1–29
  68. Stepanek E, Josph S, Campbell P, et al. Embolization of a limb metastasis in renal cell carcinoma as a palliative treatment of bone pain. Clin Radiol. 1999;54:855–857
  69. Kavolius JP, Mastorakos DP, Pavlovich C, et al. Resection of metastatic renal cell carcinoma. J Clin Oncol. 1998;16:2261–2266
  70. Kierney PC, van Heerden JA, Segura JW, et al. Surgeon’s role in the management of solitary renal cell carcinoma metastases occurring subsequent to initial curative nephrectomy: An institutional review. Ann Surg Oncol. 1994;1:345–352
  71. O’Dea MJ, Zincke H, Utz DC, et al. The treatment of renal cell carcinoma with solitary metastasis. J Urol. 1978;120:540–542
  72. Piltz S, Meimarakis G, Wichmann MW, et al. Long-term results after pulmonary resection of renal cell carcinoma metastases. Ann Thorac Surg. 2002;73:1082–1087
  73. Pfannschmidt J, Hoffmann H, Muley T, et al. Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg. 2002;74:1653–1657
  74. Alves A, Adam R, Majno P, et al. Hepatic resection for metastatic renal tumors: Is it worthwhile?. Ann Surg Oncol. 2003;10:705–710
  75. Lau WK, Zincke H, Lohse CM, et al. Contralateral adrenal metastasis of renal cell carcinoma: Treatment, outcome and a review. BJU Int. 2003;91:775–779
  76. Harada Y, Nonomura N, Kondo M, et al. Clinical study of brain metastasis of renal cell carcinoma. Eur Urol. 1999;36:230–235
  77. Badalament RA, Gluck RW, Wong GY, et al. Surgical treatment of brain metastases from renal cell carcinoma. Urology. 1990;36:112–117
  78. Ghavamian R, Klein KA, Stephens DH, et al. Renal cell carcinoma metastatic to the pancreas: Clinical and radiological features. Mayo Clin Proc. 2000;75:581–585
  79. Sohn TA, Yeo CJ, Cameron JL, et al. Renal cell carcinoma metastatic to the pancreas: Results of surgical management. J Gastrointest Surg. 2001;5:346–351
  80. Law CH, Wei AC, Hanna SS, et al. Pancreatic resection for metastatic renal cell carcinoma: Presentation, treatment, and outcome. Ann Surg Oncol. 2003;10:922–926
  81. Itano NB, Blute ML, Spotts B, et al. Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy. J Urol. 2000;164:322–325
  82. Schrodter S, Hakenberg OW, Manseck A, et al. Outcome of surgical treatment of isolated local recurrence after radical nephrectomy for renal cell carcinoma. J Urol. 2002;167:1630–1633
  83. Wiesner C, Jakse G, Rohde D. Therapy of local recurrence of renal cell carcinoma. Oncol Rep. 2002;9:189–192
  84. Tatsuta M, Shiozaki K, Masutani S, et al. Splenic and pulmonary metastases from renal cell carcinoma: Report of a case. Surg Today. 2001;31:463–465
  85. Leibovich BC, Cheville JC, Lohse CM, et al. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: A stratification tool for prospective clinical trials. J Urol. 2005;174:1759–1763
  86. Minasian LM, Motzer RJ, Gluck L, et al. Interferon alfa-2a in advanced renal cell carcinoma: Treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol. 1993;11:1368–1375
  87. Joffe JK, Banks RE, Forbes MA, et al. A phase II study of interferon-alpha, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: Clinical data and laboratory evidence of protease activation. Br J Urol. 1996;77:638–649
  88. Quesada JR, Rios A, Swanson D, et al. Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. J Clin Oncol. 1985;3:1522–1528
  89. Ljungberg B, Landberg G, Alamdari FI. Factors of importance for prediction of survival in patients with metastatic renal cell carcinoma, treated with or without nephrectomy. Scand J Urol Nephrol. 2000;34:246–251
  90. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345:1655–1659
  91. Jocham D, Richter A, Hoffmann L, et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomised controlled trial. Lancet. 2004;363:594–599
  92. Figlin RA, Thompson JA, Bukowski RM, et al. Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol. 1999;17:521–2529
  93. Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: A randomised trial. Lancet. 2001;358:966–970
  94. Flanigan RC, Mickisch G, Sylvester R, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: A combined analysis. J Urol. 2004;171:1071–1076
  95. Eggermont AM, Steller EP, Sugarbaker PH. Laparotomy enhances intraperitoneal tumor growth and abrogates the antitumor effects of interleukin-2 and lymphokine-activated killer cells. Surgery. 1987;102:71–78
  96. Wagner JR, Walther MM, Linehan WM, et al. Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place. J Urol. 1999;162:43–45
  97. Sella A, Swanson DA, Ro JY, et al. Surgery following response to interferon-alpha-based therapy for residual renal cell carcinoma. J Urol. 1993;149:19–21
  98. Bex A, Horenblas S, Meinhardt W, et al. The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ. Eur Urol. 2002;42:570–574
  99. Kim B, Louie AC. Surgical resection following interleukin 2 therapy for metastatic renal cell carcinoma prolongs remission. Arch Surg. 1992;127:1343–1349
  100. Krishnamurthi V, Novick AC, Bukowski RM. Efficacy of multimodality therapy in advanced renal cell carcinoma. Urology. 1998;51:933–937
  101. Bennett RT, Lerner SE, Taub HC, et al. Cytoreductive surgery for stage IV renal cell carcinoma. J Urol. 1995;154:32–34
  102. Walther MM, Yang JC, Pass HI, et al. Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. J Urol. 1997;158:1675–1678
  103. Bromwich E, Hendry D, Aitchison M. Cytoreductive nephrectomy: Is it a realistic option in patients with renal cancer?. BJU Int. 2002;89:523–525
  104. Mejean A, Roupret M, Larousserie F, et al. Is there a place for radical nephrectomy in the presence of metastatic collecting duct (Bellini) carcinoma?. J Urol. 2003;169:1287–1290
  105. Mosharafa A, Koch M, Shalhav A, et al. Nephrectomy for metastatic renal cell carcinoma: Indiana University experience. Urology. 2003;62:636–640
  106. Fujikawa K, Matsui Y, Miura K, et al. Serum immunosuppressive acidic protein and natural killer cell activity in patients with metastatic renal cell carcinoma before and after nephrectomy. J Urol. 2000;164:673–675
  107. Dadian G, Riches PG, Henderson DC, et al. Immunological parameters in peripheral blood of patients with renal cell carcinoma before and after nephrectomy. Br J Urol. 1994;74:15–22
  108. Montie JE, Straffon RA, Deodhar SD, et al. In vitro assessment of cell-mediated immunity in patients with renal cell carcinoma. J Urol. 1976;115:239–242
  109. Rackley R, Novick A, Klein E, et al. The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma. J Urol. 1994;152:1399–1403
  110. Mani S, Todd MB, Katz K, et al. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers. J Urol. 1995;154:35–40
  111. Figlin RA, Pierce WC, Kaboo R, et al. Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor. J Urol. 1997;158:740–745
  112. Fallick ML, McDermott DF, LaRock D, et al. Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. J Urol. 1997;158:1691–1695
  113. Levy DA, Swanson DA, Slaton JW, et al. Timely delivery of biological therapy after cytoreductive nephrectomy in carefully selected patients with metastatic renal cell carcinoma. J Urol. 1998;159:1168–1173
  114. Tigrani VS, Reese DM, Small EJ, et al. Potential role of nephrectomy in the treatment of metastatic renal cell carcinoma: A retrospective analysis. Urology. 2000;55:36–40
  115. Pantuck AJ, Belldegrun AS, Figlin RA. Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma. N Engl J Med. 2001;345:1711–1712
  116. Novick AC, Stewart BH, Straffon RA, et al. Partial nephrectomy in the treatment of renal adenocarcinoma. J Urol. 1977;118:932–936
  117. Smith RB, deKernion JB, Ehrlich RM, et al. Bilateral renal cell carcinoma and renal cell carcinoma in the solitary kidney. J Urol. 1984;132:450–454
  118. Bazeed MA, Scharfe T, Becht E, et al. Conservative surgery of renal cell carcinoma. Eur Urol. 1986;12:238–243
  119. Provet J, Tessler A, Brown J, et al. Partial nephrectomy for renal cell carcinoma: Indications, results and implications. J Urol. 1991;145:472–476
  120. Moll V, Becht E, Ziegler M. Kidney preserving surgery in renal cell tumors: Indications, techniques and results in 152 patients. J Urol. 1993;150:319–323
  121. Morgan WR, Zincke H. Progression and survival after renal-conserving surgery for renal cell carcinoma: Experience in 104 patients and extended followup. J Urology. 1990;144:852–857
  122. Belldegrun A, Tsui KH, deKernion JB, et al. Efficacy of nephron-sparing surgery for renal cell carcinoma: Analysis based on the new 1997 tumor-node-metastasis staging system. J Clin Oncol. 1999;17:2868–2875
  123. Duque JL, Loughlin KR, O’Leary MP, et al. Partial nephrectomy: Alternative treatment for selected patients with renal cell carcinoma. Urology. 1998;52:584–590
  124. Ghavamian R, Cheville JC, Lohse CM, et al. Renal cell carcinoma in the solitary kidney: An analysis of complications and outcome after nephron sparing surgery. J Urol. 2002;168:454–459
  125. Licht MR, Novick AC. Nephron sparing surgery for renal cell carcinoma. J Urol. 1993;149:1–7
  126. Lee CT, Katz J, Shi W, et al. Surgical management of renal tumors 4 cm or less in a contemporary cohort. J Urol. 2000;163:730–736

PII: S0093-7754(06)00273-9

doi: 10.1053/j.seminoncol.2006.06.007

Seminars in Oncology
Volume 33, Issue 5 , Pages 552-562 , October 2006

Article Tools